scholarly journals B12 as a Treatment for Peripheral Neuropathic Pain: A Systematic Review

Nutrients ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2221
Author(s):  
Thomas Julian ◽  
Rubiya Syeed ◽  
Nicholas Glascow ◽  
Efthalia Angelopoulou ◽  
Panagiotis Zis
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Nervous System ◽  
Neuropathic Pain ◽  
Post Herpetic Neuralgia ◽  
Peripheral Neuropathic Pain ◽  
Treatment Regimens ◽  
Level Ii ◽  
Somatosensory Nervous System

Neuropathic pain describes a range of unpleasant sensations caused by a lesion or disease of the somatosensory nervous system. The sensations caused by neuropathic pain are debilitating and improved treatment regimens are sought in order to improve the quality of life of patients. One proposed treatment for neuropathic pain is vitamin B12, which is thought to alleviate pain by a number of mechanisms including promoting myelination, increasing nerve regeneration and decreasing ectopic nerve firing. In this paper, the evidence for B12 as a drug treatment for neuropathic pain is reviewed. Twenty four published articles were eligible for inclusion in this systematic review in which a range of treatment regimens were evaluated including both B12 monotherapy and B12 in combination with other vitamins or conventional treatments, such as gabapentinoids. Overall, this systematic review demonstrates that there is currently some evidence for the therapeutic effect of B12 in the treatment of post-herpetic neuralgia (level II evidence) and the treatment of painful peripheral neuropathy (level III evidence).

scholarly journals Neuropathic pain in rheumatoid arthritis

2020 ◽  
Vol 12 (5) ◽  
pp. 60-65
Author(s):  
E. S. Filatova ◽  
A. M. Lila ◽  
V. A. Parfenov
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Chronic Pain ◽  
Nervous System ◽  
Neuropathic Pain ◽  
Pain Syndrome ◽  
Chronic Pain Syndrome ◽  
Paindetect Questionnaire ◽  
Somatosensory Nervous System

Objective: to identify the signs of neuropathic pain (NP) in patients with rheumatoid arthritis (RA) on the basis of the PainDETECT questionnaire and neurological examination.Patients and methods. A total of 208 RA patients (39 men and 169 women; mean age, 47.7 years) with chronic pain syndrome were examined. The patients underwent rheumatological and neurological examinations; NP was diagnosed using the PainDETECT questionnaire; inflammation severity (DAS28 index), pain intensity (VAS), affective disorders (HADS), and quality of life (EQ-5D) were assessed.Results and discussion. 172 (82.7%) patients had moderate and high disease activity according to the DAS28. The signs of possible and highly probable NP according to the PainDETECT questionnaire were detected in 29.8 and 26.9% of patients, respectively; they were significantly more likely to be detected in patients with more severe pain syndrome, clinically significant anxiety, and worse quality of life, but were unassociated with RA activity according to the DAS28. Somatosensory nervous system injury (polyneuropathy, tunnel syndromes, and cervical myelopathy) was found in 77.6% of patients with possible NP and in 80.4% with highly probable NP. In other patients, NP might be caused by central sensitization. Conclusion. In patients with a RA exacerbation, chronic pain syndrome is caused not only by an active inflammatory process in the joint area and adjacent tissues, but also by somatosensory nervous system injury and central sensitization.

scholarly journals ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain

2020 ◽  
Vol 21 (15) ◽  
pp. 5330 ◽  
Author(s):  
Ramona D’Amico ◽  
Daniela Impellizzeri ◽  
Salvatore Cuzzocrea ◽  
Rosanna Di Paola
Keyword(s):  
Nervous System ◽  
Neuropathic Pain ◽  
Mast Cells ◽  
Inflammatory Responses ◽  
Bioactive Lipids ◽  
Peripheral Neuropathic Pain ◽  
Novel Approach ◽  
Preclinical And Clinical Studies ◽  
Somatosensory Nervous System

Neuropathic pain results from lesions or diseases of the somatosensory nervous system and it remains largely difficult to treat. Peripheral neuropathic pain originates from injury to the peripheral nervous system (PNS) and manifests as a series of symptoms and complications, including allodynia and hyperalgesia. The aim of this review is to discuss a novel approach on neuropathic pain management, which is based on the knowledge of processes that underlie the development of peripheral neuropathic pain; in particular highlights the role of glia and mast cells in pain and neuroinflammation. ALIAmides (autacoid local injury antagonist amides) represent a group of endogenous bioactive lipids, including palmitoylethanolamide (PEA), which play a central role in numerous biological processes, including pain, inflammation, and lipid metabolism. These compounds are emerging thanks to their anti-inflammatory and anti-hyperalgesic effects, due to the down-regulation of activation of mast cells. Collectively, preclinical and clinical studies support the idea that ALIAmides merit further consideration as therapeutic approach for controlling inflammatory responses, pain, and related peripheral neuropathic pain.

Diabetic Peripheral Neuropathic Pain: Clinical and Quality-of-Life Issues

2006 ◽  
Vol 81 (4) ◽  
pp. S3-S11 ◽  
Author(s):  
Charles E. Argoff ◽  
B. Eliot Cole ◽  
David A. Fishbain ◽  
Gordon A. Irving
Keyword(s):  
Quality Of Life ◽  
Neuropathic Pain ◽  
Peripheral Neuropathic Pain ◽  
Life Issues

Peripheral neuropathic pain

2020 ◽  
Vol 47 (3) ◽  
pp. 265-283
Author(s):  
Douglas Murphy ◽  
Denise Lester ◽  
F. Clay Smither ◽  
Ellie Balakhanlou
Keyword(s):  
Nervous System ◽  
Neuropathic Pain ◽  
Peripheral Nervous System ◽  
Nerve Blocks ◽  
Peripheral Neuropathic Pain ◽  
Non Invasive ◽  
Wide Range ◽  
The Cost ◽  
And Control

Neuropathic pain (NP) can have either central nervous system causes or ones from the peripheral nervous system. This article will focus on the epidemiology, classifications, pathology, non-invasive treatments and invasive treatments as a general review of NP involving the peripheral nervous system. NP has characteristic symptomatology such as burning and electrical sensations. It occurs in up to 10% of the general population. Its frequency can be attributed to its occurrence in neck and back pain, diabetes and patients receiving chemotherapy. There are a wide range of pharmacologic options to control this type of pain and when such measures fail, numerous interventional methods can be employed such as nerve blocks and implanted stimulators. NP has a cost to the patient and society in terms of emotional consequences, quality of life, lost wages and the cost of assistance from the medical system and thus deserves serious consideration for prevention, treatment and control.

scholarly journals Prevalence of Peripheral Neuropathic Pain among Adult Diabetic Patients (T2DM) with Peripheral Neuropathy and Quality of Life of the Patients with Peripheral Neuropathic Pain

2020 ◽  
Author(s):  
Jawad Ahmad Abu-Shennar ◽  
Nurhan Bayraktar ◽  
Hatic Bebis
Keyword(s):  
Quality Of Life ◽  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Rating Scale ◽  
Assessment Tool ◽  
Study Data ◽  
Diabetic Patients ◽  
Life Questionnaire ◽  
Peripheral Neuropathic Pain

Abstract Aim The aim of the study was to assess the prevalence of diabetic peripheral neuropathic pain (DPNP) among adult patients suffering from type 2 diabetes mellitus (T2DM) with diabetic peripheral neuropathy (DPN) as well as to determine the quality of life of patients with DPNP.Materials and method The study designed in cross-sectional research model was conducted at the Jordanian Ministry of Health in Jordan, Amman during the period from 15 June 2019 to 5 October 2019. A total of 400 adult T2DM patients with DNP were recruited for the study. Data were collected by way of an assessment tool package, including descriptive data (demographics, anthropometric measurements, laboratory measurements, and clinical data), the Douleur Neuropathique4 (DN4) questionnaire, physical exam, Quality of Life Questionnaire (EQ-5D), and Numeric Pain Rating Scale (NRS). To analyze study data descriptive and inferential statistics were used.Results Results of the current study showed that the prevalence of DPNP among adult T2DM patients with DPN was high (47.8%). About half of the participants had mild or moderate pain with the most frequently reported symptoms of tingling and burning. Uncontrolled diabetes was found to be the main predictor of DPNP among patients with DPN. Participants who had DPNP reported having problems in connection with mobility, self-care, routine activities, discomfort, and anxiety or/and depression, and they had a significantly lower quality of life with poorer self-rated health status than those without DPNP. Besides, the effect of pain on their quality of life was found to be significant.Conclusion The study recommends, in accordance with the results, that strategies should be developed for an effective management of painful DPN with an integrated and interdisciplinary approach. Current clinical guideline recommendations should be followed to improve patient care and reduce the burden of the disease.

scholarly journals Prevalence of Peripheral Neuropathic Pain among Adult Diabetic Patients (T2DM) with Peripheral Neuropathy and Quality of Life of the Patients with Peripheral Neuropathic Pain

2020 ◽  
Author(s):  
Jawad Ahmad Abu-Shennar ◽  
Nurhan Bayraktar ◽  
Hatice Bebis
Keyword(s):  
Quality Of Life ◽  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Rating Scale ◽  
Assessment Tool ◽  
Study Data ◽  
Diabetic Patients ◽  
Life Questionnaire ◽  
Peripheral Neuropathic Pain

Abstract Aim: The aim of the study was to assess the prevalence of diabetic peripheral neuropathic pain (DPNP) among adult patients suffering from type 2 diabetes mellitus (T2DM) with diabetic peripheral neuropathy (DPN) as well as to determine the quality of life of patients with DPNP.Materials and method: The study designed in cross-sectional research model was conducted at the Jordanian Ministry of Health in Jordan, Amman during the period from 15 June 2019 to 5 October 2019. A total of 400 adult T2DM patients with DNP were recruited for the study. Data were collected by way of an assessment tool package, including descriptive data (demographics, anthropometric measurements, laboratory measurements, and clinical data), the Douleur Neuropathique4 (DN4) questionnaire, physical exam, Quality of Life Questionnaire (EQ-5D), and Numeric Pain Rating Scale (NRS). To analyze study data descriptive and inferential statistics were used. Results: Results of the current study showed that the prevalence of DPNP among adult T2DM patients with DPN was high (47.8%). About half of the participants had mild or moderate pain with the most frequently reported symptoms of tingling and burning. Uncontrolled diabetes was found to be the main predictor of DPNP among patients with DPN. Participants who had DPNP reported having problems in connection with mobility, self-care, routine activities, discomfort, and anxiety or/and depression, and they had a significantly lower quality of life with poorer self-rated health status than those without DPNP. Besides, the effect of pain on their quality of life was found to be significant. Conclusion: The study recommends, in accordance with the results, that strategies should be developed for an effective management of painful DPN with an integrated and interdisciplinary approach. Current clinical guideline recommendations should be followed to improve patient care and reduce the burden of the disease.

(166) Quality of life in veterans with diabetic peripheral neuropathic pain

2014 ◽  
Vol 15 (4) ◽  
pp. S17
Author(s):  
R. Masheb ◽  
K. LaChappelle ◽  
A. Heapy ◽  
D. Higgins ◽  
R. Czlapinski ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Neuropathic Pain ◽  
Peripheral Neuropathic Pain
Sign in / Sign up

Export Citation Format

Share Document